Chemokine CXCL10

Home
About
Help
History (1)
- Chemokine CXCL10
- See All Pages

"Chemokine CXCL10" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A CXC chemokine that is induced by GAMMA-INTERFERON and is chemotactic for MONOCYTES and T-LYMPHOCYTES. It has specificity for the CXCR3 RECEPTOR.

Descriptor ID	D054357
MeSH Number(s)	D12.644.276.374.200.120.500 D12.776.467.374.200.120.500 D23.125.300.120.500 D23.469.200.120.500 D23.529.374.200.120.500
Concept/Terms	Chemokine CXCL10 Chemokine CXCL10 CXCL10, Chemokine Cytokine IP-10 Protein Cytokine IP 10 Protein IP-10 Protein, Cytokine Interferon-Inducible Protein 10 Interferon Inducible Protein 10 CXC Chemokine IP-10 CXC Chemokine IP 10 Chemokine IP-10, CXC Small Inducible Cytokine B10 IFN-gamma-Inducible Protein, 10 kDa IFN gamma Inducible Protein, 10 kDa CXCL10 Chemokine Chemokine, CXCL10 gammaIP-10 Protein gammaIP 10 Protein Chemokine (C-X-C Motif) Ligand 10 Interferon-gamma-Inducible Protein of 10 kDa Interferon gamma Inducible Protein of 10 kDa

Below are MeSH descriptors whose meaning is more general than "Chemokine CXCL10".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Peptides [D12.644]
Intercellular Signaling Peptides and Proteins [D12.644.276]
Cytokines [D12.644.276.374]
Chemokines [D12.644.276.374.200]
Chemokines, CXC [D12.644.276.374.200.120]
Chemokine CXCL10 [D12.644.276.374.200.120.500]
Proteins [D12.776]
Intercellular Signaling Peptides and Proteins [D12.776.467]
Cytokines [D12.776.467.374]
Chemokines [D12.776.467.374.200]
Chemokines, CXC [D12.776.467.374.200.120]
Chemokine CXCL10 [D12.776.467.374.200.120.500]
Biological Factors [D23]
Chemotactic Factors [D23.125]
Chemokines [D23.125.300]
Chemokines, CXC [D23.125.300.120]
Chemokine CXCL10 [D23.125.300.120.500]
Inflammation Mediators [D23.469]
Chemokines [D23.469.200]
Chemokines, CXC [D23.469.200.120]
Chemokine CXCL10 [D23.469.200.120.500]
Intercellular Signaling Peptides and Proteins [D23.529]
Cytokines [D23.529.374]
Chemokines [D23.529.374.200]
Chemokines, CXC [D23.529.374.200.120]
Chemokine CXCL10 [D23.529.374.200.120.500]

Below are MeSH descriptors whose meaning is related to "Chemokine CXCL10".

Below are MeSH descriptors whose meaning is more specific than "Chemokine CXCL10".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Chemokine CXCL10" by people in this website by year, and whether "Chemokine CXCL10" was a major or minor topic of these publications.

Bar chart showing 35 publications over 17 distinct years, with a maximum of 4 publications in 2004 and 2014 and 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	0	1	1
2002	0	1	1
2003	0	1	1
2004	0	4	4
2007	1	2	3
2008	0	1	1
2010	0	1	1
2012	0	2	2
2013	0	2	2
2014	2	2	4
2016	0	3	3
2017	0	4	4
2018	0	2	2
2019	1	1	2
2020	1	1	2
2022	1	0	1
2023	0	1	1

Below are the most recent publications written about "Chemokine CXCL10" by people in Profiles.

Richmond JM, Patel D, Watanabe T, Chen HW, Martyanov V, Werner G, Garg M, Haddadi NS, Refat MA, Mahmoud BH, Wong LD, Dresser K, Deng A, Zhu JL, McAlpine W, Hosler GA, Feghali-Bostwick CA, Whitfield ML, Harris JE, Torok KS, Jacobe HT. CXCL9 Links Skin Inflammation and Fibrosis through CXCR3-Dependent Upregulation of Col1a1 in Fibroblasts. J Invest Dermatol. 2023 07; 143(7):1138-1146.e12.

View in: PubMed
Tang Q, Sousa J, Echeverria D, Fan X, Hsueh YC, Afshari K, MeHugh N, Cooper DA, Vangjeli L, Monopoli K, Okamura K, Biscans A, Clauss A, Harris JE, Khvorova A. RNAi-based modulation of IFN-? signaling in skin. Mol Ther. 2022 08 03; 30(8):2709-2721.

View in: PubMed
Bugide S, Gupta R, Green MR, Wajapeyee N. EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner. Proc Natl Acad Sci U S A. 2021 07 27; 118(30).

View in: PubMed
Riding RL, Richmond JM, Fukuda K, Harris JE. Type I interferon signaling limits viral vector priming of CD8+ T cells during initiation of vitiligo and melanoma immunotherapy. Pigment Cell Melanoma Res. 2021 07; 34(4):683-695.

View in: PubMed
Groover MK, Richmond JM. Potential therapeutic manipulations of the CXCR3 chemokine axis for the treatment of inflammatory fibrosing diseases. F1000Res. 2020; 9:1197.

View in: PubMed
Walrath T, Malizia RA, Zhu X, Sharp SP, D'Souza SS, Lopez-Soler R, Parr B, Kartchner B, Lee EC, Stain SC, Iwakura Y, O'Connor W. IFN-? and IL-17A regulate intestinal crypt production of CXCL10 in the healthy and inflamed colon. Am J Physiol Gastrointest Liver Physiol. 2020 03 01; 318(3):G479-G489.

View in: PubMed
Lee MH, Gallo PM, Hooper KM, Corradetti C, Ganea D, Caricchio R, Gallucci S. The cytokine network type I IFN-IL-27-IL-10 is augmented in murine and human lupus. J Leukoc Biol. 2019 10; 106(4):967-975.

View in: PubMed
Muralidharan S, Lim A, Catalano D, Mandrekar P. Human Binge Alcohol Intake Inhibits TLR4-MyD88 and TLR4-TRIF Responses but Not the TLR3-TRIF Pathway: HspA1A and PP1 Play Selective Regulatory Roles. J Immunol. 2018 04 01; 200(7):2291-2303.

View in: PubMed
Seliga A, Lee MH, Fernandes NC, Zuluaga-Ramirez V, Didukh M, Persidsky Y, Potula R, Gallucci S, Sriram U. Kallikrein-Kinin System Suppresses Type I Interferon Responses: A Novel Pathway of Interferon Regulation. Front Immunol. 2018; 9:156.

View in: PubMed
Liu LY, Strassner JP, Refat MA, Harris JE, King BA. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017 Oct; 77(4):675-682.e1.

View in: PubMed

People

Explore

Similar Concepts

Top Journals